Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the patients cancer.
Esophageal Cancer|Gastric Cancer|GE Junction Cancer
DRUG: Taxotere|DRUG: Cisplatin|DRUG: Irinotecan
To assess the response rate of patients with esophageal or gastric carcinoma to weekly Taxotere, Cisplatin, and Irinotecan (CPT-11).
To assess the duration of response and overall survival of patients with esophageal or gastric carcinoma to weekly Taxotere, Cisplatin, and Irinotecan.|To assess the toxicity of this combination in esophageal or gastric carcinoma., 4 years
* Taxotere, cisplatin and irinotecan will be administered to the patient once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks).
* Patients will also receive corticosteroids, intravenous hydration and anti-emetic therapy prior to each treatment.
* A physical exam and bloodwork will be done each week of the treatment and every 2 cycles, reassessment of the tumor by the same imaging method to determine the baseline size will be conducted.
* Patients will remain on the study unless disease progression or intolerable toxicity occur.